South African pharmaceuticals company Ascendis Health’s board of directors continues to consider nonbinding proposals and expressions of interest (EoIs) for the acquisition of Ascendis Health shares.
The company on November 12 said it continues to receive a number of these, though it advised shareholders that they should “base their investment decisions regarding Ascendis Health shares on announcements published by the company itself and not on information from other sources”, as that information may not necessarily be accurate or based on “a complete set of facts”.
When an EoI is received, the board of directors of the company will assess it carefully from both a quantitative and qualitative perspective, it assured shareholders.
To the extent that the terms of any EoI received have merit and, having regard primarily for its regulatory obligations and also taking into account any confidentiality requirements stipulated in the relevant EoI, the board will publish the appropriate announcement at the appropriate time, it noted.